An interventional study of Fig extract cream and Placebo cream in Subacute and Chronic Eczematous Dermatitis Volunteers, sponsored by Chulalongkorn University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Chulalongkorn University · Not applicable, Interventional, and Supportive care
This study aims to evaluate the efficacy and safety of a cream containing fig extract in volunteers with subacute and chronic eczematous dermatitis. The affected area of subacute and chronic eczematous dermatitis in each participant will be equally divided into two sections (left and right) using block randomization. One section (Area A) will receive the fig extract cream, while the other section (Area B) will receive a placebo cream as the control. All study assessments, including clinical assessments, skin parameter measurements, patient-reported outcomes, and adverse event assessments, will be performed at baseline and at 1, 2, and 3 weeks after treatment initiation.
The severity of subacute and chronic eczematous dermatitis will be assessed using the SCORAD Index and the Eczema Area and Severity Index (EASI). Clinical photographs will be taken to assess the affected area. Skin parameters, including erythema, melanin, hydration, and transepidermal water loss, will also be evaluated. Participants will additionally assess pruritus using the Visual Analogue Scale (VAS) and quality of life using the Dermatology Life Quality Index (DLQI).
1,425 studies on the registry are indexed under Dermatitis; 127 are open to participants now.
This study's planned enrollment of 20 is below the median of 64 across 1,124 interventional studies indexed under Dermatitis.
Browse Dermatitis studies →Chulalongkorn University is the lead sponsor of 320 studies on the registry; 64 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Apply the assigned cream to the designated areas, twice daily, in the morning and evening, for 3 weeks.
Other: Fig extract cream
Apply the assigned cream to the designated areas, twice daily, in the morning and evening, for 3 weeks.
Other: Placebo cream
Fig extract cream
Placebo cream
The severity of subacute and chronic eczematous dermatitis
The severity of subacute and chronic eczematous dermatitis will be assessed using the SCORAD Index. The SCORAD Index ranges from 0 to 103, with higher scores indicating greater severity of eczematous dermatitis.
Time frame: 3 weeks
Eczema Area and Severity Index (EASI)
The severity of subacute and chronic eczematous dermatitis will be assessed using the Eczema Area and Severity Index (EASI). The EASI Index ranges from 0 to 72, with higher scores indicating greater severity of eczematous dermatitis.
Time frame: 3 weeks
Area of dermatitis
Clinical photographs will be taken to assess the affected area, with a reduction in the affected area indicating improvement after treatment.
Time frame: 3 weeks
Erythema level
Erythema level will be assessed using a Mexameter. Higher erythema levels indicate greater severity of eczematous dermatitis.
Time frame: 3 weeks
Melanin level
Melanin level will be assessed using a Mexameter.Higher melanin levels indicate greater severity of eczematous dermatitis.
Time frame: 3 weeks
Skin hydration level
Skin hydration level will be assessed using a Corneometer. Lower hydration levels indicate greater severity of eczematous dermatitis.
Time frame: 3 weeks
Transepidermal water loss level
Transepidermal water loss level will be assessed using a Tewameter. Higher transepidermal water loss levels indicate greater severity of eczematous dermatitis.
Time frame: 3 weeks
Pruritus score
Pruritus score using the Visual Analogue Scale (VAS), ranging from 0 to 10, with higher scores indicating greater severity of itching.
Time frame: 3 weeks
Quality of life score
Quality of life acore using the Dermatology Life Quality Index (DLQI), with higher scores indicating a greater impact of eczematous dermatitis on quality of life.
Time frame: 3 weeks
Adverse events from using the products
Adverse events will be assessed by recording the presence or absence of itching, erythema, swelling, vesicles, abnormal breathing, and asthma symptoms.
Time frame: 3 weeks
Satisfaction Score
Satisfaction Score will be assessed using a numerical rating scale from 0 to 10, where 0 indicates not satisfied at all and 10 indicates very satisfied.
Time frame: 3 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.